RankAlpha logo
Back to Rankings

ANIK

Anika TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Q1 showed 13% revenue growth, 64% gross margin, and $4.3m adjusted EBITDA, so if OEM timing normalizes and the pipeline keeps advancing, ANIK can still re-rate as a self-help plus pipeline story [#8-K-2026-04-29] [#10-Q-2026-04-30].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.8.
What can break
Cash and liquidity deserve monitoring: cash fell to $41.0m, operating cash flow was negative, and buybacks continued, which could pressure flexibility if clinical spending stays elevated [#10-Q-2026-04-30].
Momentum
85
Value
62
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.50 · Bull $18.50 · Bear $10.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-30 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum85 · Δ7d +0.8
Value62 · Δ7d +0.3
Sentiment51 · Δ7d +1.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
34% active weight
Current posture
7d trendSoftening
Δ7d
+0.8
Δ21d
+1.8
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.4
Sentiment
51
33% active weight
Current posture
7d trendImproving
Δ7d
+1.2
Δ21d
+3.7
Why this grade

Composite grade A. Momentum 85.5 / Value 62.3 / Sentiment 51.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$194.66M
Beta
0.43
Shares Out
14.42M
P/E (TTM)
10.1
P/S (TTM)
1.66
P/FCF (TTM)
210.75
Rev YoY
-28.2%
EPS YoY
+89.1%
Gross Margin
+54.3%
Op Margin
+19.6%
Net Debt
-$55.63M
Current Ratio
6.18
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology